Navigation Links
Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
Date:5/28/2009

y is substantially prolonged relative to topical protein therapy, which must generally be re-applied daily.

Update on MATRIX Phase 2b Clinical Study

On May 6, 2009, Cardium announced the completion of recruitment for the Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of Excellarate for the treatment of non-healing diabetic foot ulcers. The MATRIX Data and Safety Monitoring Board has reviewed safety data collected from study participants as of April 21, 2009 and reported that Excellarate appears to be both safe and well tolerated, with no serious adverse events attributable to the study product. Approximately 80% of the patients recruited in the MATRIX study have already completed their initial evaluation period. The Company expects to report on key efficacy data in September 2009, including the percentage of patients achieving complete wound closure, the rate of wound closure and the reduction of wound size at various time points. Patients with wounds that successfully closed are also followed up for an additional 12 weeks following closure to demonstrate durability.

Cardium announced on May 7, 2009, that in parallel with the Phase 2b study and in anticipation of a Phase 3 clinical study and future commercialization, the Company's continuing process development activities have led to an important breakthrough in product formulation that not only significantly simplifies the use of Excellarate, but opens the door to additional potential applications. The product formulation that was used in the Phase 2b study required storage in a minus 70 degrees Celsius freezer and a two syringe mixing process prior to treatment. The new product formulation is designed to be maintained in a physician's office using a standard refrigerator (at a temperature of about 4 degrees Celsius) and to have a shelf life of 12-18 months. It will also be formulated as an easy-to-use single syringe that
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Cardium Completes $6.0 Million Financing
6. Cardium Announces Investor Presentation and Corporate Update Webcast
7. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
8. Cardium Reports on Exchange Listing With NYSE Alternext US
9. Cardiums InnerCool Announces Launch of New Enhanced Website
10. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
11. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... of adults with ADHD improve when their ADHD ... College of Medicine researchers., At least 25 percent ... a parent with ADHD. , "Parents with ADHD ... parenting techniques, including inconsistent disciplinary practices, making ineffectual ... Waxmonsky, associate professor of psychiatry. "Having a parent ...
(Date:7/31/2014)... 2014 Jacuzzi Luxury Bath, ... has launched a new and improved website to meet ... The Jacuzzi Luxury Bath website has been redesigned to ... and quality represented by the company’s products. The design ... and inspirational bathroom applications. “The site reflects our Jacuzzi® ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
(Date:7/31/2014)... According to a new market report ... Market - Global Forecast, Market Share, Size, Growth and ... fixation devices market is estimated at USD 6.1 billion ... CAGR of 7.2% from 2014 to 2019, to reach ... Globally, the orthopedic trauma fixation devices market is witnessing ...
Breaking Medicine News(10 mins):Health News:Parenting skills improve in ADHD parents with medication 2Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3Health News:Orthopedic Trauma Fixation Devices Market: Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020 2Health News:Orthopedic Trauma Fixation Devices Market: Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020 3
... Allows Pharmaceutical Brand Managers to Build Patient-Flow Models ... Decision Resources, one of the world,s leading ... healthcare issues, finds that use of Novartis, Diovan ... Cozaar is influenced by physician perception that the ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) President and ... a new healthcare reform coalition:"PhRMA echoes the sentiment shared ... is critical for all Americans to have access to ... central goal in mind, we are working with a ...
... stroke specialists, especially in rural or other underserved areas; ... a "mini" or "warning" stroke, should be treated with ... two separate scientific statements and a policy statement published ... Association . , Telemedicine Statement Highlights: , ...
... May 11 David Cornfield, MD, the chief ... Lucile Packard Children,s Hospital at Stanford, has been ... (SPR).(Photo: http://www.newscom.com/cgi-bin/prnh/20090511/SF14213 )Beginning this month, Cornfield ... pediatricians for a one-year term. "It,s a great ...
... WASHINGTON, May 11 President Obama and U.S. Senate ... protection laws as suggested by health insurers last week, ... said Consumer Watchdog in a letter to the president ... every state over the last 10 years were made ...
... run on behalf of 1.275 million Americans living with spinal ... Dana Reeve Foundation today announced Matthew Reeve, son of Christopher ... Reeve Foundation, will run the 2009 ING New York City ... inspired to compete on behalf of the 1.275 million Americans ...
Cached Medicine News:Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 2Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 3Health News:PhRMA Statement on Healthcare Reform Coalition 2Health News:PhRMA Statement on Healthcare Reform Coalition 3Health News:PhRMA Statement on Healthcare Reform Coalition 4Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:Packard/Stanford Physician to Lead Society for Pediatric Research 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 3Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 3
(Date:7/31/2014)... Cryoport, Inc. (OTCBB: CYRX) today announced financial results for ... Recent Operating Highlights , Achieved 92% ... period ended June 30, 2014 compared to the prior ... expand Cryoport,s global reach using the ,powered by Cryoport ... an immunotherapy and vaccine development services company, to support ...
(Date:7/31/2014)... 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... second quarter 2014, on Thursday, August 7, 2014 before ... live webcast and conference call at 8:00 a.m. Eastern ... will host the call and webcast to discuss financial ... be accessed by calling (800) 708-4540 (domestic) or (847) ...
(Date:7/31/2014)... N.J. , July 31, 2014  Celsion Corporation ... Company will host a conference call to discuss its ... on Thursday, August 7, 2014. To participate in the ... America ) or 1-785-830-1924 (International/Toll) and ask for ... Code: 8283269) to register ten minutes before the call ...
Breaking Medicine Technology:Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... Clinic,s Top 10 Medical Innovations for 2010 list features a ... developed to treat everything from deafness and Parkinson,s disease to ... devices and therapies was selected by a panel of Cleveland ... Cleveland Clinic,s 2009 Medical Innovation Summit , which ...
... Medco Health Solutions, Inc. (NYSE: MHS ) is ... getting the most value out of their Medicare prescription drug ... different plan options - Choice , Access , ... access to a vast array of medications, pharmacy locations, and ...
Cached Medicine Technology:Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 2Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 3Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 4Medco's 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs 2Medco's 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs 3Medco's 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs 4
... Package is a solid solution ... The package includes the Vibratome ... mounting blocks, v-block adapter, specimen ... rotating stage assembly for ease ...
... Professional Package is the best ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a sapphire blade for the ...
... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... System provides a versatile means of sectioning ... The 1500 employs a vibrating blade ... embedding. The creation of artifacts, the ... activities, and other deleterious effect inherent in ...
Medicine Products: